Submitted by pharmamanufacturing on Thu, 11/04/2010 - 21:22.
A growing number of pharma CEOs are now dealing with the consequences of failing to care about workplace realities and what Toyota called the gemba, or place where truth will be found.
If the idea of reading a book on ethics or philosophy is too off-putting....after all, it has been a rough week....why not simply listen to The Clash's hit song "Should I Stay or Should I Go?" The answer's right there. "If I go there will be trouble, and if I stay it will be double."
Submitted by pharmamanufacturing on Thu, 11/04/2010 - 02:37.
Pharma whistleblowers don't always fare too well...especially those who deal with the invisible world of manufacturing. Remember Mark Livingston and the Wyeth Sarbanes-Oxley case? However, Cheryl Eckard, who pointed out manufacturing deficiencies at GSK's Cidra, Puerto Rico, plant has received a $96-million payment. For more from The Guardian, read on. They've included
Submitted by pharmamanufacturing on Wed, 10/27/2010 - 19:41.
Cautionary tale for execs in pharma (or any industry) on the limits of "doing more with less," ignoring technical operations and focusing on financial balance sheets at the expense of quality and safety. Frontline's documentary on the BP disaster and Texas City refinery tragedy.
Submitted by pharmamanufacturing on Thu, 10/21/2010 - 19:56.
Getting some good news for a change, Johnson & Johnson ranks fourth among all companies in Newsweek's annual Green Rankings, ahead of other pharmaceuticals that made the top 100, including: Baxter, BMS, Allergan, Pfizer, Abbott, Lilly, Merck, and Hospira. To see how various drug makers fared among the top 500, use the drop-down menu on the link above to locate the pharmaceutical sector standings.
Submitted by pharmamanufacturing on Tue, 10/19/2010 - 21:35.
In the cover story of this month's issue of Pharmaceutical Manufacturing--Workforce Training: Embracing the "Necessary Evil"--I quote several industry consultants who suggest that FDA inspectors are taking a much closer looking at worker training issues than they have in the past, which is evidenced by an increase in mentions of training in recent warning letters.
Submitted by pharmamanufacturing on Wed, 10/13/2010 - 17:51.
Business journalists lately have been writing of the demise of the U.S. pharma sector, with some describing it as going the way of the Big Three U.S automakers, and others seeing it as "despairing its future."
Submitted by pharmamanufacturing on Thu, 09/23/2010 - 16:25.
Today, Chris Watts, last of the PAT Team leaders to have stayed at FDA, will be leaving the Agency. He has been with FDA for eight years, and plans to return to California, and the San Diego area. Of his stint at the Agency, he writes, "The experience far exceeded my expectations . . . and I can only hope that future opportunities offer as much." Of course, biopharm company recruiters will want to take note that such talent might be available, locally.
Submitted by pharmamanufacturing on Wed, 09/15/2010 - 20:58.
Drug manufacturers have been coming to grips with how to leverage social media, from Tweets to blogs, without overstepping the bounds of compliance. Johnson & Johnson and a number of companies have taken the lead, as our Senior Editor for Digital Media Michele Vaccarello Wagner has written.
Submitted by pharmamanufacturing on Tue, 09/14/2010 - 16:19.
FDA has signaled this past summer that it will toughen its stance on the degree to which drug manufacturers must oversee and audit the activity of their vendor partners.
Today, Chris Watts, last of the PAT Team leaders to have stayed at FDA, will be leaving the Agency. He has been with FDA for eight years, and plans to return to California, and the San Diego area. Of his stint at the Agency, he writes, "The experience far exceeded my expectations . . . and I can only hope that future opportunities offer as much." Of course, biopharm company recruiters will want to take note that such talent might be available, locally.
